Feuil1
SEMESTRE 1
S1 2022 (en million d'euros) Total chiffre d'affaires Var. TCC Var. Publiée Etats-Unis Var. TCC Europe Var. TCC Reste du monde Var. TCC
Dupixent 3,577 44.4% 56.2% 2,653 38.0% 450 55.0% 474 75.5%
Aubagio 1,017 -4.4% 2.3% 689 -6.3% 269 1.5% 59 -9.4%
Lemtrada 45 0.0% 4.7% 19 -15.0% 12 9.1% 14 16.7%
Kevzara 172 46.0% 52.2% 90 64.0% 53 29.3% 29 36.4%
Neurologie & Immunologie 1,234 0.7% 7.3% 798 -1.8% 334 5.4% 102 4.1%
Cerezyme 367 5.5% 7.0% 94 2.4% 126 1.6% 147 11.0%
Cerdelga 139 7.3% 13.0% 75 6.3% 55 7.8% 9 12.5%
Myozyme 487 -3.3% 0.8% 163 -17.8% 206 2.5% 118 10.7%
Nexviazyme 73 6700.0% 7200.0% 63 - 3 200.0% 7 -
Fabrazyme 458 5.8% 11.2% 221 5.3% 116 4.5% 121 8.1%
Aldurazyme 133 4.9% 8.1% 29 0.0% 45 4.7% 59 7.4%
Total maladies rares 1,695 6.7% 10.9% 645 7.4% 553 4.2% 497 9.0%
Jevtana 203 -20.8% -15.4% 142 8.4% 19 -74.7% 42 -8.7%
Fasturtec 86 8.1% 16.2% 54 14.0% 24 9.1% 8 -22.2%
Libtayo 88 44.1% 49.2% - - 70 43.8% 18 45.5%
Sarclisa 129 67.6% 74.3% 55 78.6% 38 40.7% 36 89.5%
Total Oncologie 507 7.4% 13.4% 251 20.0% 151 -12.8% 105 20.0%
Alprolix 237 9.0% 18.5% 198 10.5% - - 39 2.6%
Eloctate 291 -3.2% 4.7% 232 -2.8% - - 59 -4.8%
Cablivi 97 9.5% 15.5% 48 2.3% 47 17.5% 2 0.0%
Total maladies hématologiques rares 629 3.7% 11.9% 482 3.8% 47 17.5% 100 -2.0%
Médecine de spécialités 7,642 19.8% 27.8% 4,829 20.4% 1,535 13.6% 1,278 25.7%
Lovenox 714 -9.5% -7.0% 7 -60.0% 353 -4.1% 354 -12.7%
Toujeo 541 4.4% 8.2% 128 -4.2% 211 8.2% 202 5.9%
Plavix 508 0.0% 4.7% 5 -20.0% 52 -13.3% 451 2.1%
Multaq 178 7.9% 17.9% 160 9.8% 9 -25.0% 9 28.6%
Thymoglobulin 210 12.8% 22.1% 121 7.9% 17 6.3% 72 23.6%
Mozobil 124 6.4% 12.7% 71 6.7% 31 6.9% 22 4.8%
Praluent 197 79.8% 89.4% 55 860.0% 108 42.7% 34 33.3%
Soliqua/iGlarLixi 106 10.0% 17.8% 56 -3.8% 15 7.1% 35 43.5%
Rezurock 84 - - 84 - - - - -
Autres produits stratégiques 543 -0.8% 4.0% 86 -36.6% 182 4.0% 275 15.2%
Produits Stratégiques 3,205 5.3% 10.4% 773 13.4% 978 3.5% 1,454 2.9%
Lantus 1,271 -6.7% -1.4% 425 -10.3% 223 -9.3% 623 -3.3%
Aprovel 245 15.5% 22.5% 3 0.0% 42 -10.6% 200 24.0%
Autres produits non stratégiques 2,320 -7.9% -5.2% 196 -6.3% 593 -10.1% 1,531 -7.3%
Produits Non Stratégiques 3,836 -6.4% -2.5% 624 -9.0% 858 -9.9% 2,354 -4.2%
Ventes Industrielles 316 -18.9% -16.8% 13 -54.2% 294 -13.7% 9 -61.9%
Médecine Générale 7,357 -2.3% 1.9% 1,410 1.0% 2,130 -4.8% 3,817 -2.0%
Total Pharma 14,999 7.7% 13.7% 6,239 15.4% 3,665 2.1% 5,095 3.9%
Vaccins Polio / Petussis / HIB 1,202 9.1% 14.2% 224 -15.4% 161 11.0% 817 17.5%
Vaccins Rappel 261 18.4% 26.7% 144 15.0% 74 12.1% 43 48.1%
Vaccins Méningite 265 -21.3% -15.6% 185 -19.3% 6 500.0% 74 -30.2%
Vaccins contre la grippe 181 -10.7% -7.7% 12 - 37 105.6% 132 -28.7%
Vaccins pour voyageurs et autres vaccins endémiques 243 73.7% 82.7% 74 83.3% 42 215.4% 127 47.6%
Vaccins 2,198 7.8% 13.5% 678 -2.1% 321 31.1% 1,199 8.2%
Allergie 418 13.4% 21.9% 249 13.5% 37 8.8% 132 14.7%
Toux et rhume 219 96.4% 99.1% - - 122 165.2% 97 46.9%
Douleur 618 13.8% 17.0% 103 2.2% 289 15.6% 226 17.1%
Santé Digestive 661 11.5% 15.4% 62 -8.2% 224 12.0% 375 15.1%
Bien-être physique 173 5.0% 8.8% - - 11 -15.4% 162 6.8%
Bien-être mental 123 13.1% 15.0% 24 -4.3% 60 9.1% 39 34.5%
Hygiène personnelle 279 1.6% 10.7% 209 -0.5% 1 -50.0% 69 10.2%
Autres 102 -22.3% -21.5% (2) -175.0% 37 -32.1% 67 -6.8%
Santé Grand Public 2,593 13.1% 17.8% 645 2.6% 781 19.4% 1,167 14.9%
Total Sanofi 19,790 8.4% 14.2% 7,562 12.4% 4,767 6.2% 7,461 6.2%
TRIMESTRE 2
T2 2022 (en million d'euros) Total chiffre d'affaires Var. TCC Var. Publiée Etats-Unis Var. TCC Europe Var. TCC Reste du monde Var. TCC
Dupixent 1,963 43.4% 57.9% 1,477 37.9% 239 56.6% 247 65.3%
Aubagio 526 -2.2% 6.5% 360 -2.8% 137 3.0% 29 -17.1%
Lemtrada 20 0.0% 5.3% 8 -30.0% 6 0.0% 6 100.0%
Kevzara 77 30.4% 37.5% 40 40.0% 25 25.0% 12 18.2%
Neurologie & Immunologie 623 1.1% 9.5% 408 -0.6% 168 5.7% 47 -2.0%
Cerezyme 202 18.8% 22.4% 49 0.0% 66 8.2% 87 42.6%
Cerdelga 72 11.5% 18.0% 39 9.4% 28 12.0% 5 25.0%
Myozyme 252 -3.6% 1.6% 81 -21.7% 103 1.0% 68 18.5%
Nexviazyme 43 3900.0% 4200.0% 37 - 2 100.0% 4 -
Fabrazyme 238 9.3% 16.7% 116 6.2% 58 7.4% 64 17.0%
Aldurazyme 64 7.0% 12.3% 16 0.0% 21 10.0% 27 8.7%
Total maladies rares 891 11.6% 17.4% 338 7.6% 279 6.5% 274 22.9%
Jevtana 105 -15.8% -7.9% 74 8.2% 8 -73.3% 23 -4.3%
Fasturtec 46 7.7% 17.9% 30 18.2% 12 9.1% 4 -33.3%
Libtayo 47 36.4% 42.4% - - 36 38.5% 11 28.6%
Sarclisa 64 52.5% 60.0% 30 62.5% 16 14.3% 18 90.0%
Total Oncologie 263 8.0% 16.4% 134 19.2% 72 -11.1% 57 17.4%
Alprolix 129 16.0% 29.0% 106 12.0% - - 23 35.3%
Eloctate 153 -3.5% 6.3% 124 -3.5% - - 29 -3.2%
Cablivi 51 4.3% 10.9% 26 9.5% 24 0.0% 1 -
Total maladies hématologiques rares 336 5.5% 15.9% 259 5.1% 24 0.0% 53 10.4%
Médecine de spécialités 4,076 21.6% 32.0% 2,616 21.4% 782 15.2% 678 30.9%
Lovenox 337 -10.9% -8.2% 2 -50.0% 168 -7.7% 167 -13.7%
Toujeo 267 2.4% 8.1% 70 5.2% 107 6.9% 90 -4.5%
Plavix 247 0.0% 5.6% 2 -33.3% 26 -16.1% 219 3.0%
Multaq 91 2.5% 15.2% 82 2.9% 4 -33.3% 5 66.7%
Thymoglobulin 113 12.0% 22.8% 65 3.6% 9 12.5% 39 27.6%
Mozobil 66 6.9% 13.8% 40 9.4% 16 6.7% 10 0.0%
Praluent 128 147.9% 166.7% 55 - 55 41.0% 18 77.8%
Soliqua/iGlarLixi 53 4.3% 15.2% 26 -11.1% 7 14.3% 20 33.3%
Rezurock 43 - - 43 - - - - -
Autres produits stratégiques 266 -3.5% 3.5% 47 -35.8% 87 -2.2% 132 17.0%
Produits Stratégiques 1,611 6.0% 12.8% 432 21.3% 479 0.6% 700 2.4%
Lantus 600 -12.1% -5.8% 217 -19.0% 111 -7.4% 272 -8.2%
Aprovel 120 13.1% 21.2% 2 100.0% 21 -12.5% 97 20.3%
Autres produits non stratégiques 1,133 -8.5% -4.8% 101 -10.1% 293 -11.3% 739 -7.1%
Produits Non Stratégiques 1,853 -8.6% -3.8% 320 -16.0% 425 -10.4% 1,108 -5.5%
Ventes Industrielles 133 -33.3% -30.7% 3 -84.6% 126 -30.7% 4 -
Médecine Générale 3,597 -4.1% 1.4% 755 0.3% 1,030 -8.9% 1,812 -2.6%
Total Pharma 7,673 7.9% 15.7% 3,371 16.0% 1,812 0.1% 2,490 4.9%
Vaccins Polio / Petussis / HIB 589 7.9% 13.3% 99 -17.0% 83 23.9% 407 12.4%
Vaccins Rappel 152 32.1% 43.4% 91 24.6% 43 34.4% 18 77.8%
Vaccins Méningite 153 -24.7% -17.7% 109 -26.7% 4 300.0% 40 -25.9%
Vaccins contre la grippe 115 -5.9% -3.4% - - 33 266.7% 82 -28.2%
Vaccins pour voyageurs et autres vaccins endémiques 145 83.8% 95.9% 51 100.0% 25 200.0% 69 54.5%
Vaccins 1,178 8.7% 15.3% 372 -3.5% 188 59.8% 618 5.5%
Allergie 192 16.2% 29.7% 118 11.7% 20 25.0% 54 23.7%
Toux et rhume 98 74.5% 78.2% - - 56 166.7% 42 17.6%
Douleur 304 5.8% 10.5% 57 -2.0% 138 7.8% 109 7.3%
Santé Digestive 336 9.3% 15.9% 33 -19.4% 112 18.9% 191 10.1%
Bien-être physique 85 2.6% 9.0% - - 5 0.0% 80 2.7%
Bien-être mental 57 0.0% 5.6% 12 -8.3% 26 0.0% 19 6.3%
Hygiène personnelle 149 5.5% 17.3% 113 6.3% - -100.0% 36 6.5%
Autres 44 -29.0% -29.0% 2 -100.0% 18 -33.3% 24 -27.8%
Santé Grand Public 1,265 9.1% 16.2% 335 3.1% 375 17.9% 555 6.8%
Total Sanofi 10,116 8.1% 15.7% 4,078 12.7% 2,375 5.7% 3,663 5.3%

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Sanofi SA published this content on 28 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2022 07:57:01 UTC.